These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12733711)

  • 21. Final adult height in long-term growth hormone-treated achondroplasia patients.
    Harada D; Namba N; Hanioka Y; Ueyama K; Sakamoto N; Nakano Y; Izui M; Nagamatsu Y; Kashiwagi H; Yamamuro M; Ishiura Y; Ogitani A; Seino Y
    Eur J Pediatr; 2017 Jul; 176(7):873-879. PubMed ID: 28501952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth and growth hormone therapy in children with achondroplasia: a two-year experience.
    Stamoyannou L; Karachaliou F; Neou P; Papataxiarchou K; Pistevos G; Bartsocas CS
    Am J Med Genet; 1997 Oct; 72(1):71-6. PubMed ID: 9295079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of growth hormone treatment in children with hypochondroplasia: comparison with an historical cohort.
    Pinto G; Cormier-Daire V; Le Merrer M; Samara-Boustani D; Baujat G; Fresneau L; Viaud M; Souberbielle JC; Pineau JC; Polak M
    Horm Res Paediatr; 2014; 82(6):355-63. PubMed ID: 25323764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prenatal sonographic diagnosis of hypochondroplasia in a high-risk fetus.
    Huggins MJ; Mernagh JR; Steele L; Smith JR; Nowaczyk MJ
    Am J Med Genet; 1999 Nov; 87(3):226-9. PubMed ID: 10564875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia.
    Heuertz S; Le Merrer M; Zabel B; Wright M; Legeai-Mallet L; Cormier-Daire V; Gibbs L; Bonaventure J
    Eur J Hum Genet; 2006 Dec; 14(12):1240-7. PubMed ID: 16912704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia.
    Bellus GA; McIntosh I; Smith EA; Aylsworth AS; Kaitila I; Horton WA; Greenhaw GA; Hecht JT; Francomano CA
    Nat Genet; 1995 Jul; 10(3):357-9. PubMed ID: 7670477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial.
    Hertel NT; Eklöf O; Ivarsson S; Aronson S; Westphal O; Sipilä I; Kaitila I; Bland J; Veimo D; Müller J; Mohnike K; Neumeyer L; Ritzen M; Hagenäs L
    Acta Paediatr; 2005 Oct; 94(10):1402-10. PubMed ID: 16299871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth-promoting effect of human growth hormone on patients with achondroplasia.
    Okabe T; Nishikawa K; Miyamori C; Sato T
    Acta Paediatr Jpn; 1991 Jun; 33(3):357-62. PubMed ID: 1785332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.
    Matsushita M; Hasegawa S; Kitoh H; Mori K; Ohkawara B; Yasoda A; Masuda A; Ishiguro N; Ohno K
    Endocrinology; 2015 Feb; 156(2):548-54. PubMed ID: 25456072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth Hormone Treatment for Achondroplasia.
    Yorifuji T; Higuchi S; Kawakita R
    Pediatr Endocrinol Rev; 2018 Sep; 16(Suppl 1):123-128. PubMed ID: 30378790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short children born small for gestational age and treated with growth hormone for three years have an important catch-down five years after discontinuation of treatment.
    Fjellestad-Paulsen A; Simon D; Czernichow P
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1234-9. PubMed ID: 15001616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Present status of the use of growth hormone in short children with bone diseases (diseases of the skeleton).
    Kanaka-Gantenbein C
    J Pediatr Endocrinol Metab; 2001 Jan; 14(1):17-26. PubMed ID: 11220700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect.
    Wit JM; Rekers-Mombarg LT; Cutler GB; Crowe B; Beck TJ; Roberts K; Gill A; Chaussain JL; Frisch H; Yturriaga R; Attanasio AF
    J Pediatr; 2005 Jan; 146(1):45-53. PubMed ID: 15644821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation in the gene encoding the fibroblast growth factor receptor-3 in Korean children with achondroplasia.
    Yang SW; Kitoh H; Yamada Y; Goto H; Ogasawara N
    Acta Paediatr Jpn; 1998 Aug; 40(4):324-7. PubMed ID: 9745773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism.
    Bonaventure J; Rousseau F; Legeai-Mallet L; Le Merrer M; Munnich A; Maroteaux P
    Am J Med Genet; 1996 May; 63(1):148-54. PubMed ID: 8723101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.
    Xie Y; Su N; Jin M; Qi H; Yang J; Li C; Du X; Luo F; Chen B; Shen Y; Huang H; Xian CJ; Deng C; Chen L
    Hum Mol Genet; 2012 Sep; 21(18):3941-55. PubMed ID: 22634226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial.
    Van Pareren Y; Mulder P; Houdijk M; Jansen M; Reeser M; Hokken-Koelega A
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3584-90. PubMed ID: 12915640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Further delineation of achondroplasia-hypochondroplasia complex with long-term survival.
    González-Del Angel A; Rius R; Alcántara-Ortigoza MA; Spector E; Del Castillo V; Mata-García LE
    Am J Med Genet A; 2018 May; 176(5):1225-1231. PubMed ID: 29681095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations in the fibroblast growth factor receptor 3 (FGFR3) cause achondroplasia, hypochondroplasia, and thanatophoric dysplasia: Taiwanese data.
    Tsai FJ; Tsai CH; Chang JG; Wu JY
    Am J Med Genet; 1999 Sep; 86(3):300-1. PubMed ID: 10482885
    [No Abstract]   [Full Text] [Related]  

  • 40. FGFR3 gene mutations in transmembrane domain in Chinese achondroplasia and hypochondroplasia patients.
    Yan-Ling G; Ji-Hong N; Guo-Qiang L; Wei W; De-Fen W
    Horm Res; 1998; 49 Suppl 1():57. PubMed ID: 9554479
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.